The Effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients

Lipids

Volumn 45, Issue 5, 2010, Pages 445-450

  Nakou, E S ^a   Filippatos, T D ^a   Agouridis, A P ^a   Kostara, C ^a   Bairaktari, E T ^a   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein C II; Apolipoprotein C III; Cholesterol; Ezetimibe; Orlistat; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SYNTHESIS; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN C-II; APOLIPOPROTEIN C-III; AZETIDINES; DIET, FAT-RESTRICTED; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES;

EID: 77953231187     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-010-3409-0     Document Type: Article

References (48)

1. MC Jong MH Hofker LM Havekes 1999 Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3 Arterioscler Thromb Vasc Biol 19 472 484 1:CAS:528:DyaK1MXitFGns70%3D
2. CS Wang 1991 Structure and functional properties of apolipoprotein C-II Prog Lipid Res 30 253 258 10.1016/0163-7827(91)90022-W 1:CAS:528: DyaK38Xht1egtrk%3D
3. DC Chan MM Chen EM Ooi GF Watts 2008 An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int J Clin Pract 62 799 809 10.1111/j.1742-1241.2007.01678.x 1:CAS:528:DC%2BC3cXksVKnu78%3D (Pubitemid 351533666)
4. TD Filippatos DP Mikhailidis 2009 Lipid-lowering drugs acting at the level of the gastrointestinal tract Curr Pharm Des 15 490 516 10.2174/138161209787315738 1:CAS:528:DC%2BD1MXkvVSnt7k%3D
5. M Garcia-Calvo J Lisnock HG Bull BE Hawes DA Burnett MP Braun JH Crona HR Davis Jr DC Dean PA Detmers MP Graziano M Hughes DE Macintyre A Ogawa KA O'Neill SP Iyer DE Shevell MM Smith YS Tang AM Makarewicz F Ujjainwalla SW Altmann KT Chapman NA Thornberry 2005 The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1) Proc Natl Acad Sci USA 102 8132 8137 10.1073/pnas.0500269102 1:CAS:528:DC%2BD2MXlsV2msbY%3D (Pubitemid 40800055)
6. DN Kiortsis TD Filippatos MS Elisaf 2005 The effects of orlistat on metabolic parameters and other cardiovascular risk factors Diabetes Metab 31 15 22 10.1016/S1262-3636(07)70161-1 1:CAS:528:DC%2BD2MXivVOku7w%3D
7. TD Filippatos CS Derdemezis IF Gazi ES Nakou DP Mikhailidis MS Elisaf 2008 Orlistat-associated adverse effects and drug interactions: a critical review Drug Saf 31 53 65 10.2165/00002018-200831010-00005 1:CAS:528: DC%2BD1cXisFCit7Y%3D
8. T Filippatos C Derdemezis M Elisaf 2009 Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors Clin Lipidol 4 331 341 10.2217/clp.09.25 1:CAS:528:DC%2BD1MXmtlKmsrw%3D
9. TD Filippatos IF Gazi EN Liberopoulos VG Athyros MS Elisaf AD Tselepis DN Kiortsis 2007 The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome Atherosclerosis 193 428 437 10.1016/j.atherosclerosis. 2006.07.010 1:CAS:528:DC%2BD2sXotVClsbk%3D (Pubitemid 47058108)
10. TD Filippatos DN Kiortsis EN Liberopoulos M Georgoula DP Mikhailidis MS Elisaf 2005 Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study Curr Med Res Opin 21 1997 2006 10.1185/ 030079905X75078 1:CAS:528:DC%2BD28XhtF2ju7o%3D (Pubitemid 41803111)
11. TD Filippatos EN Liberopoulos M Kostapanos IF Gazi EC Papavasiliou DN Kiortsis AD Tselepis MS Elisaf 2008 The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome Diabetes Obes Metab 10 476 483 10.1111/j.1463-1326.2007.00733.x 1:CAS:528:DC%2BD1cXnsFKqu74%3D (Pubitemid 351639090)
12. ES Nakou TD Filippatos M Georgoula DN Kiortsis AD Tselepis DP Mikhailidis MS Elisaf 2008 The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia Curr Med Res Opin 24 1919 1929 10.1185/03007990802177150 1:CAS:528:DC%2BD1cXhtVGhsLbP
13. ES Nakou TD Filippatos DN Kiortsis CS Derdemezis AD Tselepis DP Mikhailidis MS Elisaf 2008 The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia Expert Opin Pharmacother 9 3151 3158 10.1517/14656560802548430 1:CAS:528: DC%2BD1cXhsVensr3M
14. I Sakurabayashi Y Saito T Kita Y Matsuzawa Y Goto 2001 Reference intervals for serum apolipoproteins A-I, A-II, B, C-II, C-III, and E in healthy Japanese determined with a commercial immunoturbidimetric assay and effects of sex, age, smoking, drinking, and Lp(a) level Clin Chim Acta 312 87 95 10.1016/S0009-8981(01)00591-5 1:CAS:528:DC%2BD3MXnt1Whs7w%3D (Pubitemid 32913584)
15. EM Ooi PH Barrett DC Chan GF Watts 2008 Apolipoprotein C-III: understanding an emerging cardiovascular risk factor Clin Sci (Lond) 114 611 624 10.1042/CS20070308 1:CAS:528:DC%2BD1cXksF2mtrs%3D (Pubitemid 351589061)
16. M Yamamoto SY Morita M Kumon M Kawabe K Nishitsuji H Saito A Vertut-Doi M Nakano T Handa 2003 Effects of plasma apolipoproteins on lipoprotein lipase-mediated lipolysis of small and large lipid emulsions Biochim Biophys Acta 1632 31 39 1:CAS:528:DC%2BD3sXktVyitr8%3D
17. CS Wang WJ McConathy HU Kloer P Alaupovic 1985 Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III J Clin Invest 75 384 390 10.1172/JCI111711 1:CAS:528:DyaL2MXht12ku78%3D
18. HN Ginsberg NA Le IJ Goldberg JC Gibson A Rubinstein P Wang-Iverson R Norum WV Brown 1986 Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo J Clin Invest 78 1287 1295 10.1172/JCI112713 1:CAS:528:DyaL2sXhs1Wqtw%3D%3D
19. MC Jong PC Rensen VE Dahlmans H van der Boom TJ van Berkel LM Havekes 2001 Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice J Lipid Res 42 1578 1585 1:CAS:528:DC%2BD3MXotFGqu70%3D
20. WJ McConathy JC Gesquiere H Bass A Tartar JC Fruchart CS Wang 1992 Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III J Lipid Res 33 995 1003 1:CAS:528:DyaK3sXisFSgsbc%3D
21. M Kalogirou V Tsimihodimos I Gazi T Filippatos V Saougos AD Tselepis DP Mikhailidis M Elisaf 2007 Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia Curr Med Res Opin 23 1169 1176 10.1185/030079907X188062 1:CAS:528:DC%2BD2sXnt1WhurY%3D (Pubitemid 46799601)
22. C Derdemezis T Filippatos A Tselepis D Mikhailidis M Elisaf 2008 Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study Expert Opin Pharmacother 9 1829 1837 10.1517/14656566.9.11.1829 1:CAS:528:DC%2BD1cXos1Chu7g%3D
23. MS Kostapanos HJ Milionis TD Filippatos ES Nakou ET Bairaktari AD Tselepis MS Elisaf 2007 A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia Clin Ther 29 1403 1414 10.1016/j.clinthera.2007.07.019 1:CAS:528:DC%2BD2sXhtVemurjJ (Pubitemid 47348117)
24. WA Bradley SL Hwang JB Karlin AH Lin SC Prasad AM Gotto Jr SH Gianturco 1984 Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins J Biol Chem 259 14728 14735 1:CAS:528:DyaL2cXmtVylurw%3D
25. SA Brown DP Via AM Gotto Jr WA Bradley SH Gianturco 1986 Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting Biochem Biophys Res Commun 139 333 340 10.1016/S0006-291X(86)80118-8 1:CAS:528:DyaL28XlslSjtLw%3D
26. CJ Packard T Demant JP Stewart D Bedford MJ Caslake G Schwertfeger A Bedynek J Shepherd D Seidel 2000 Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions J Lipid Res 41 305 318 1:CAS:528:DC%2BD3cXjtlOjtr8%3D
27. MJ Caslake CJ Packard 2004 Phenotypes, genotypes and response to statin therapy Curr Opin Lipidol 15 387 392 10.1097/01.mol.0000137225.46654.4d 1:CAS:528:DC%2BD2cXlsV2hsrw%3D (Pubitemid 39061617)
28. AJ Tremblay B Lamarche JS Cohn JC Hogue P Couture 2006 Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia Arterioscler Thromb Vasc Biol 26 1101 1106 10.1161/01.ATV.0000216750.09611.ec 1:CAS:528:DC%2BD28XjsVersLc%3D (Pubitemid 43732118)
29. D Masuda Y Nakagawa-Toyama K Nakatani M Inagaki K Tsubakio-Yamamoto JC Sandoval T Ohama M Nishida M Ishigami S Yamashita 2009 Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia Eur J Clin Invest 39 689 698 10.1111/j.1365-2362.2009.02163.x 1:CAS:528: DC%2BD1MXhtValtrjE
30. CS Wang D Downs A Dashti KW Jackson 1996 Isolation and characterization of recombinant human apolipoprotein C-II expressed in Escherichia coli Biochim Biophys Acta 1302 224 230
31. SS Fojo HB Brewer 1992 Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II J Intern Med 231 669 677 10.1111/j.1365-2796.1992.tb01256.x 1:CAS:528:DyaK3sXjs1Kquw%3D%3D
32. MC Jong LM Havekes 2000 Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice Int J Tissue React 22 59 66 1:CAS:528:DC%2BD3cXlvVykt78%3D
33. G Baggio E Manzato C Gabelli R Fellin S Martini GB Enzi F Verlato MR Baiocchi DL Sprecher ML Kashyap, et al. 1986 Apolipoprotein C-II deficiency syndrome clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients J Clin Invest 77 520 527 10.1172/JCI112332 1:STN:280:DyaL287ht1Gnsg%3D%3D
34. M Reina JD Brunzell SS Deeb 1992 Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes J Lipid Res 33 1823 1832 1:CAS:528:DyaK3sXnvVKgsw%3D%3D
35. NS Shachter T Hayek T Leff JD Smith DW Rosenberg A Walsh R Ramakrishnan IJ Goldberg HN Ginsberg JL Breslow 1994 Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice J Clin Invest 93 1683 1690 10.1172/JCI117151 1:CAS:528:DyaK2cXivFGqur4%3D
36. RC Kowal J Herz KH Weisgraber RW Mahley MS Brown JL Goldstein 1990 Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein J Biol Chem 265 10771 10779 1:CAS:528:DyaK3cXkvFems7g%3D
37. V Clavey S Lestavel-Delattre C Copin JM Bard JC Fruchart 1995 Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E Arterioscler Thromb Vasc Biol 15 963 971 1:CAS:528:DyaK2MXnsVehtrw%3D
38. CP Lucas MN Boldrin GM Reaven 2003 Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia Am J Cardiol 91 961 964 10.1016/S0002-9149(03)00112-7 1:CAS:528:DC%2BD3sXislenur0%3D (Pubitemid 36398529)
39. JB Reitsma M Castro Cabezas TW de Bruin DW Erkelens 1994 Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor Metabolism 43 293 298 10.1016/0026-0495(94)90095-7 1:STN:280: DyaK2c7oslKgug%3D%3D (Pubitemid 24100497)
40. KC Tan AW Tso SC Tam RW Pang KS Lam 2002 Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus Diabet Med 19 944 948 10.1046/j.1464-5491.2002.00823.x 1:CAS:528:DC%2BD38XpsV2ks78%3D (Pubitemid 35356921)
41. T Filippatos V Tsimihodimos M Kostapanos C Kostara E Bairaktari D Kiortsis M Elisaf 2008 Analysis of the 6-month effect of orlistat, alone or in combination with fenofibrate, administration on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome J Clin Lipidol 2 279 284 10.1016/j.jacl.2008.06.001
42. ML Fernandez S Metghalchi S Vega-Lopez K Conde-Knape TG Lohman ZR Cordero-Macintyre 2004 Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women J Nutr Biochem 15 717 721 10.1016/j.jnutbio.2004.07.001 1:CAS:528:DC%2BD2cXhtVyqsLzE (Pubitemid 40018114)
43. N Gervaise MA Garrigue G Lasfargues P Lecomte 2000 Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes Diabetologia 43 703 708 10.1007/s001250051366 1:CAS:528:DC%2BD3cXjsFKisr8%3D
44. SJ Lee H Campos LA Moye FM Sacks 2003 LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients Arterioscler Thromb Vasc Biol 23 853 858 10.1161/01.ATV.0000066131.01313.EB 1:CAS:528:DC%2BD3sXjtlaktLo%3D (Pubitemid 36566177)
45. Y Gerber U Goldbourt S Segev D Harats 2003 Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case-control study Prev Med 37 18 22 10.1016/S0091-7435(03)00051-3 1:CAS:528:DC%2BD3sXksVGktrs%3D (Pubitemid 36687861)
46. G Luc C Fievet D Arveiler AE Evans JM Bard F Cambien JC Fruchart P Ducimetiere 1996 Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde J Lipid Res 37 508 517 1:CAS:528:DyaK28XisFartL4%3D
47. HN Hodis WJ Mack SP Azen P Alaupovic JM Pogoda L LaBree LC Hemphill DM Kramsch DH Blankenhorn 1994 Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin Circulation 90 42 49 1:STN:280:DyaK2c3pvVWrsQ%3D%3D
48. FM Sacks P Alaupovic LA Moye TG Cole B Sussex MJ Stampfer MA Pfeffer E Braunwald 2000 VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial Circulation 102 1886 1892 1:CAS:528:DC%2BD3cXnvV2qtLw%3D